A Phase II Study of Neoadjuvant Cisplatin and Gemcitabine Plus Sorafenib for Patients With Transitional-Cell Carcinoma of the Bladder.

Trial Profile

A Phase II Study of Neoadjuvant Cisplatin and Gemcitabine Plus Sorafenib for Patients With Transitional-Cell Carcinoma of the Bladder.

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 06 Jun 2017

At a glance

  • Drugs Sorafenib (Primary) ; Cisplatin; Gemcitabine
  • Indications Bladder cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 06 Jun 2017 Results assessing molecular features underlying response to neoadjuvant gemcitabine, cisplatin, and sorafenib in muscle-invasive urothelial bladder carcinoma patients, presented at the 53rd Annual Meeting of the American Society of Clinical Oncology.
    • 16 May 2017 Results presented at the 112th Annual Meeting of the American Urological Association
    • 18 Feb 2017 Results presented at the 2017 Genitourinary Cancers Symposium
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top